drugset / Trial / NCT06492395
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for large hepatocellular carcinoma (\> 7cm) with portal vein tumor thrombosis (PVTT).
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Len+DEB-TACE | Unknown | 8 mg | Oral |
| Subject | Len+DEB-TACE | Unknown | 12 mg | Oral |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Leucovorin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Subject | fluorouracil | Small molecule | — | Other |
| Background | Pirarubicin | Small molecule | — | — |